Bioxyne Ltd - Company Profile

Powered by

All the sales intelligence you need on Bioxyne Ltd in one solution.

  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Bioxyne Ltd fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Bioxyne Ltd.

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Bioxyne Ltd (Bioxyne) is a life sciences company. It manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative novel medicines. Bioxyne focuses on the pharmaceutical manufacturing and wholesale supply of novel medicines, medicinal cannabis, psilocybin, and 4-Methylenedioxymethamphetamine (MDMA) through BLS Wholesalers Pty Limited; the manufacture and distribution of consumer health products, including cannabidiol and functional mushrooms under the Dr Watson brand across the UK, Europe, and Japan; and the wholesale distribution of patented probiotics for gastrointestinal health and immunity, primarily to the US. The company has manufacturing and distribution centers in Australia, Japan, the UK, and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Gain a 360-degree view of Bioxyne Ltd and make more informed decisions for your business Gain a 360-degree view of Bioxyne Ltd and make more informed decisions for your business Learn more
Headquarters Australia

Address Suite 506 Level 5 50 Clarence Street, Sydney, New South Wales, 2000


Telephone 61 2 90788180

No of Employees 16

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BXN (ASX)

Revenue (2024) $19.3M 203.5% (2024 vs 2023)

EPS XYZ

Net Income (2024) XYZ 136.8% (2024 vs 2023)

Market Cap* $148.5M

Net Profit Margin (2024) XYZ 112.1% (2024 vs 2023)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Bioxyne Ltd premium industry data and analytics

6

Clinical Trials

Determine Bioxyne Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

Products and Services

Products Brands
Novel Medicines Dr Watson
Medicinal Cannabis Breathe Life Sciences
Psilocybin BLS Clinics
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Bioxyne Ltd portfolio and identify potential areas for collaboration Understand Bioxyne Ltd portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Contracts/Agreements In December, the company's subsidiary, Breathe Life Sciences (BLS), entered into a manufacturing and supply agreement with Remidose LATAM SRL, to facilitate Bioxyne's entry into the medicinal cannabis markets of Costa Rica and Panama.
2024 New Products/Services In August, the company manufactured and delivered Australia’s first pharmaceutical cannabis pastilles (Gummies or Edibles).
2024 Contracts/Agreements In May, the company entered into a commercial supply and collaboration agreement with Cy Biopharma AG of Switzerland.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Bioxyne Ltd Probiotec Ltd BLIS Technologies Ltd Amplia Therapeutics Ltd BioCeuticals Pty Ltd
Headquarters Australia Australia New Zealand Australia Australia
City Sydney Melbourne Dunedin Melbourne Surry Hills
State/Province New South Wales Victoria Otago Victoria New South Wales
No. of Employees 16 111 39 1 -
Entity Type Public Private Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Samuel Watson Chief Executive Officer; Managing Director Executive Board 2023 -
Jason Hine Chief Operating Officer; Director Executive Board 2023 -
Guy Robertson Chief Financial Officer; Secretary Senior Management 2016 -
Anthony Ho Chairman Non Executive Board 2012 -
Macdarragh O'Neill Head - Production (GMP); Director - BLS Wholesalers Pty Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Bioxyne Ltd key executives to enhance your sales strategy Gain insight into Bioxyne Ltd key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?